Pulmonx (4NI) Price & Analysis

0 Followers

4NI Stock Chart & Stats

€2.04

€0.00(0.00%)

At close: Jul 28 4:00 PM EDT

€2.04

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.99 - €2.18

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€76.44M

Enterprise Value€55.32M

Total Cash (Recent Filing)€55.84M

Total Debt (Recent Filing)€56.21M

Price to Earnings (P/E)―

Beta1.19

Next Earnings

Feb 24, 2027

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.15

Shares Outstanding42,948,270

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.22

Price to Book (P/B)1.66

Price to Sales (P/S)0.99

P/FCF Ratio-2.73

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€3.33

Price Target Upside63.04% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.94

Revenue Forecast (FY)€81.39M

Bulls Say, Bears Say

Bulls Say

Return To Revenue GrowthThe return to global year-over-year growth indicates that Pulmonx’s commercial reset is beginning to translate into renewed demand. Growth across both U.S. and international markets, rather than one isolated geography, supports a more durable recovery in procedure volumes and treating-center activity.

Improving Operating LeverageMeaningful reductions in operating losses and expenses show that Pulmonx is gaining cost discipline while continuing to invest in growth initiatives. If revenue expansion continues, this lower expense base should allow incremental sales to convert more efficiently toward eventual cash-flow breakeven.

AeriSeal Market ExpansionAeriSeal provides a potential second growth avenue beyond the existing Zephyr valve franchise. Successful trial completion and commercialization could broaden Pulmonx’s addressable market, diversify future revenue sources, and strengthen its long-term platform in interventional emphysema treatment.

Bears Say

Persistent Cash BurnPulmonx continues to consume substantial cash because operating losses are translating broadly into negative cash flow. Even with expected improvement, ongoing funding needs reduce financial flexibility and make progress toward break-even dependent on sustained revenue growth and successful expense control.

Rising Leverage And Shrinking EquityHigher leverage alongside a shrinking equity base leaves Pulmonx with a thinner buffer against continued losses. The company has extended debt maturity, but rising financial obligations can constrain investment choices and increase financing risk if the expected improvement in profitability takes longer than planned.

Inexperienced U.S. SalesforceA relatively junior sales organization can slow the conversion of hospital opportunities into productive treatment centers and consistent procedure volumes. Uneven representative ramp times may therefore make commercial execution less predictable, even after open positions have been substantially filled.

Pulmonx News

Pulmonx price target raised to $4 from $2.50 at Stifel

Stifel raised the firm’s price target on Pulmonx (LUNG) to $4 from $2.50 and keeps a Buy rating...

59m ago

LUNG

Pulmonx reports Q3 EPS (19c), consensus (26c)

Reports Q3 revenue $22.84M, consensus $21.94M. “We are very pleased to have returned to year-over-year revenue growth in...

16h ago

LUNG

Pulmonx backs FY26 revenue view $90M-$92M, consensus $90.55M

The company said, “Pulmonx (LUNG) continues to expect revenue for the full year 2026 to be in the...

16h ago

LUNG

Is LUNG a Buy, Before Earnings?

Pulmonx Corporation (LUNG) is scheduled to report 3rd quarter earnings on 10/27/2026, after the market closes. Regarding Q3...

3d ago

LUNG

Pulmonx management to meet virtually with Lake Street

Virtual Meeting to be held on August 27 hosted by Lake Street. Published first on TheFly – the...

2M ago

LUNG

Pulmonx Corporation Earnings Call Signals Cautious Turn

Pulmonx Corporation (($LUNG)) has held its Q2 earnings call. Read on for the main highlights of the call....

3M ago

LUNG

Pulmonx reports Q2 EPS (24c), consensus (28c)

Reports Q2 revenue $22.75M, consensus $22.39M. “We are pleased with the progress we made in the second quarter...

3M ago

LUNG

Pulmonx backs FY26 revenue view $90M-$92M, consensus $90.77M

The company said, “Pulmonx (LUNG) continues to expect revenue for the full year 2026 to be in the...

3M ago

LUNG

Pulmonx Shareholders Back Board, Auditor and Pay Program

Pulmonx ( ($LUNG) ) has provided an update. On June 4, 2026, Pulmonx Corporation held its 2026 Annual...

5M ago

LUNG

Pulmonx Earnings Call: Margin Gains Amid Growth Pause

Pulmonx Corporation (($LUNG)) has held its Q1 earnings call. Read on for the main highlights of the call....

6M ago

LUNG

Pulmonx reports Q1 EPS (33c), consensus (33c)

Reports Q1 revenue $20.59M, consensus $20.43M. “During the first quarter we initiated our refreshed U.S. commercial strategies and...

6M ago

LUNG

Pulmonx backs FY26 revenue view $90M-$92M, consensus $90.87M

The company said, “Pulmonx (LUNG) continues to expect revenue for the full year 2026 to be in the...

6M ago

LUNG

Pulmonx Faces Legal, Regulatory and Financial Risks From Off‑Label Use of Its Products

Pulmonx Corporation (LUNG) has disclosed a new risk, in the Corporate Activity and Growth category. Pulmonx Corporation faces...

8M ago

LUNG

Pulmonx Earnings Call: Cost Discipline Amid Growth Pause

Pulmonx Corporation (($LUNG)) has held its Q4 earnings call. Read on for the main highlights of the call....

8M ago

LUNG

4NI FAQ

What was Pulmonx’s price range in the past 12 months?

Pulmonx lowest stock price was €0.99 and its highest was €2.18 in the past 12 months.

What is Pulmonx’s market cap?

Pulmonx’s market cap is €76.44M.

When is Pulmonx’s upcoming earnings report date?

Pulmonx’s upcoming earnings report date is Feb 24, 2027 which is in 119 days.

How were Pulmonx’s earnings last quarter?

Pulmonx released its earnings results on Oct 27, 2026. The company reported -€0.171 earnings per share for the quarter, beating the consensus estimate of -€0.231 by €0.06.

Is Pulmonx overvalued?

According to Wall Street analysts Pulmonx’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pulmonx pay dividends?

Pulmonx does not currently pay dividends.

What is Pulmonx’s EPS estimate?

Pulmonx’s EPS estimate is -0.19.

How many shares outstanding does Pulmonx have?

Pulmonx has 42,948,270 shares outstanding.

What happened to Pulmonx’s price movement after its last earnings report?

Pulmonx reported an EPS of -€0.171 in its last earnings report, beating expectations of -€0.231. Following the earnings report the stock price went up 5.607%.

Which hedge fund is a major shareholder of Pulmonx?

Currently, no hedge funds are holding shares in DE:4NI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pulmonx Stock Smart Score

Outperform

Fundamentals

Return on Equity

-98.23%

Trailing 12-Months

Asset Growth

-22.05%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Pulmonx

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.

Pulmonx (4NI) Earnings & Revenues

Historic Earnings Reports

4NI Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call was strongly constructive. Pulmonx returned to year-over-year revenue growth in both the U.S. and international businesses, improved gross margin, reduced operating expenses and losses, reiterated its full-year revenue outlook, and reported progress in its sales organization, clinical programs, China restart, and liquidity position. The main challenges were the relatively inexperienced salesforce, continued cash utilization and net losses, uncertainty around China's shipment timing, and the lack of 2027 guidance.View all DE:4NI earnings summaries

4NI Stock 12 Month Forecast

Average Price Target

€3.33

▲(63.04% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","5":"€5","1.25":"€1.25","2.5":"€2.5","3.75":"€3.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4.4946002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€4.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.3260041480000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€3.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.2473001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.25</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.25,2.5,3.75,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.69,1.905738476923077,2.1214769538461535,2.3372154307692306,2.5529539076923076,2.7686923846153846,2.9844308615384616,3.200169338461538,3.415907815384615,3.631646292307692,3.847384769230769,4.063123246153846,4.278861723076923,{"y":4.4946002,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.69,1.815846472923077,1.9416929458461538,2.067539418769231,2.1933858916923077,2.3192323646153845,2.445078837538462,2.5709253104615386,2.696771783384616,2.8226182563076927,2.9484647292307695,3.0743112021538463,3.2001576750769236,{"y":3.3260041480000004,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.69,1.7328692384615385,1.7757384769230768,1.8186077153846154,1.8614769538461537,1.9043461923076923,1.9472154307692306,1.9900846692307692,2.0329539076923075,2.075823146153846,2.1186923846153847,2.161561623076923,2.2044308615384614,{"y":2.2473001,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.34,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.839,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >